Tuesday, Jan 31

FDA Approves Vismodegib for Basal Cell Carcinoma

The FDA has approved Erivedge (vismodegib) for the treatment of basal cell carcinoma, the most common type of skin cancer.

Inlyta Approved to Treat Patients with Advanced Kidney Cancer

The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

Tuesday, Jan 17

Herceptin-Tykerb Combo Nearly Twice as Effective as Single-Drug Therapy

Combining GlaxoSmithKline’s Tykerb drug with Roche Holding AG’s Herceptin to treat breast cancer was almost twice as effective as single-drug therapy, according to researchers in a 23-country clinical trial.

Genetic Mutation Tied to Inherited Prostate Cancer

Scientists say they've identified the first genetic mutation with a major effect on the risk of prostate cancer that runs in families and strikes men early, by age 55.

Tuesday, Jan 10

First Patient Enrolled for Phase 3 Trial of Biosimilar Erythropoietin

Hospira, Inc., announced enrollment of the first patient in a Phase 3 U.S. clinical program for its biosimilar erythropoietin (EPO). The study will compare safety and efficacy of Hospira's EPO and the reference product, Amgen's Epogen, in patients with renal (kidney) dysfunction who have anemia.